Wes is a Senior Consultant with 35 years of leading global analytical teams with a variety of biological product types.

A global analytical leader who delivers targeted results through technical expertise and project management skills

Experienced in moving analytical projects through development to commercialization

Wes is an accomplished pharmaceutical professional with extensive experience in various management and technical level positions. During his career, Wes and his teams have provided technical support to the introduction, analytical validation, technology transfer, and ongoing manufacture of several commercial biotechnology and natural products. Along with personal technical accomplishments, Wes has led groups providing process, formulation, and protein characterization analytical support. Commercial biological products Wes has supported include proteins, oligonucleotides, heparin, vaccines, blood products, and antibody-drug conjugates.

Wes has a Ph.D. in Microbiology from Louisiana State University and a B.S. in Medical Technology from Kansas State University. He was a postdoctoral associate at The Ohio State University in molecular biology and cloning.

Wes has a long history as a volunteer with the United States Pharmacopeia (USP) that started in 1992. He has led many USP Expert Committees and Expert Panels resulting in new USP reference standards and chapters, and his teams have been recognized by receiving USP awards for their rapid response to health crises.

Wes lives in the St. Louis, Missouri area and has worked globally from that location for many years in support of many development and commercial pharmaceutical projects.

Examples of projects completed:

  • Chairman of USP Heparin Advisory Panel, consisting of FDA/industry/academic members, that introduced a revolutionary new heparin monograph to the industry to modernized heparin testing to protect public safety and resulted in the widely cited publication: The US Regulatory and Pharmacopeia Response to the Global Heparin Contamination Crisis. Nature Biotechnology, Volume 34, Number 6, pages 625 – 630, 2016
  • Analytical lead for process observation and analytical characterization project ($42 million impact)
  • Analytical Lead on the team that obtained FDA and EMEA approval of Somavert® (pegylated growth hormone antagonist)
  • Analytical Director that obtained FDA approval of Posilac®, recombinant bovine somatotropin (growth hormone) for enhanced dairy production. Posilac® was a pioneering product in veterinary products produced through recombinant DNA technology.